The Next Stop for Pharma Outsourcing
Increasing consumption and steady innovation will be key trends in the small molecule drug market. But what does this mean in terms of contract manufacturing?
Matthew Moorcroft |
In the May issue of The Medicine Maker, I looked at how the field of contract manufacturing has evolved over the past 40 years (1). As a quick recap, my colleagues and I at Cambrex have been studying how contract manufacturing for small molecule drugs has changed since the 1970s (2). Our research showed that there have been four key phases to date: the early years (pre-1975 to 1980), the growth years (1980-1996), the competitive years (1996 to 2010), and the resurgent years (2010 to 2015). Our research was based not only on global API consumption data, the number of new drug approvals and the number of new entrants in the contract manufacturing organization (CMO) space, but also on expert views from leading figures working within the sector.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.